An update on indications for platelet transfusion

Abstract

Platelets are very commonly prescribed blood components, and in many settings, their use is increasing. They may be used either prophylactically (to attempt to prevent bleeding) or therapeutically (to treat bleeding when it occurs). This review provides a summary of the major clinical settings in which platelet transfusions are currently used. Most platelet transfusions are provided prophylactically to thrombocytopenic haematology/oncology patients, although bleeding risks and rates appear to vary substantially between individual patients. Other contexts include major haemorrhage, surgery and invasive procedures, and patients in critical care and neonatal intensive care. Since platelet transfusions carry risks and costs, and evidence of benefit for platelet transfusion in many clinical settings is not yet available, additional clinical studies to establish the utility of platelet transfusions and other interventions to prevent or manage bleeding are needed.

Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion

“…This can quickly destroy the transfused platelets, causing poor post-transfusion platelet recovery. The second type is minor ABO-incompatibility, which occurs when the donor's plasma has antibodies against the recipient's ABO antigen on RBC [6][7][8][9].…”

“…Platelet concentrates (PC) are indicated therapeutically to treat bleeding manifestations in patients with thrombocytopenia or qualitative functional defects (inherited or acquired). PC may also be administered prophylactically to prevent bleeding when the platelet count is below the acceptable limit, such as before a surgical procedure [ 8 ].…”